Artus Therapeutics is a pre-clinical stage biotech company focused on discovery and development of small molecule therapeutics for inflammatory and metabolic diseases by targeting gut barrier dysfunction. Barrier dysfunction is a common baseline pathology observed in several inflammatory, autoimmune, and neuronal disorders. The company’s unique drug design and development platform have the potential to transform the treatment paradigm for barrier dysfunction diseases. Based in Boston, MA, Artus was founded by Harvard and MIT trained scientists and entrepreneurs with strong expertise in gastrointestinal.